Summary
A Consensus Development Conference was held at the National Institutes of Health from September 29-October 1, 1980, to address issues concerning the role of carcinoembryonic antigen (CEA) as a marker in the management of cancer. The panel met following formal presentations and discussions to assess the issues based on the evidence presented. These issues included: Should CEA be used in cancer screening? Is CEA helpful in cancer diagnosis? What does CEA tell about the extent and outcome of cancer? Is CEA helpful in monitoring cancer treatment? This paper constitutes the panel's findings.
This is a preview of subscription content, log in via an institution to check access.
Author information
Authors and Affiliations
Additional information
The “Journal of Cancer Research and Clinical Oncology” publishes in loose succession “Editorials” and “Guest Editorials” on current and/or controversial problems in experimental and clinical oncology. These contributions represent exclusively the personal opinion of the author. The Editors
This paper is the official report of the panel members, listed above, resulting from the National Institutes of Health Consensus Development Conference on “CEA (Carcinoembryonic Antigen): Its Role as a Marker in the Management of Cancer”. This consensus conference was sponsored by the National Cancer Institute, assisted by the Office for Medical Applications of Research, Office of the Director, National Institutes of Health, Bethesda, MD, USA. The conference was organized by Dr. K. R. McIntire and Mr. L. P. Greenberg, Diagnosis Branch, National Cancer Institute, Bethesda, MD
Rights and permissions
About this article
Cite this article
Goldenberg, D.M., Neville, A.M., Carter, A.C. et al. CEA (carcinoembryonic antigen): Its role as a marker in the management of cancer. J Cancer Res Clin Oncol 101, 239–242 (1981). https://doi.org/10.1007/BF00410109
Issue Date:
DOI: https://doi.org/10.1007/BF00410109